Natera (NASDAQ:NTRA) PT Raised to $145.00 at Canaccord Genuity Group

Natera (NASDAQ:NTRA) had its price objective upped by equities researchers at Canaccord Genuity Group from $130.00 to $145.00 in a report issued on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the medical research company’s stock. Canaccord Genuity Group’s target price points to a potential upside of 21.52% from the stock’s previous close.

A number of other equities analysts have also weighed in on the stock. UBS Group lowered their price target on shares of Natera from $160.00 to $145.00 and set a “buy” rating on the stock in a research report on Friday, August 9th. Stephens reaffirmed an “overweight” rating and set a $125.00 target price on shares of Natera in a research note on Friday, August 9th. StockNews.com raised shares of Natera from a “sell” rating to a “hold” rating in a research report on Tuesday, August 20th. Piper Sandler increased their price objective on shares of Natera from $120.00 to $150.00 and gave the company an “overweight” rating in a research report on Tuesday, August 13th. Finally, Robert W. Baird increased their price objective on shares of Natera from $117.00 to $120.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. One investment analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Natera presently has a consensus rating of “Moderate Buy” and an average price target of $120.07.

Natera Stock Up 1.0 %

NASDAQ:NTRA traded up $1.21 during midday trading on Tuesday, reaching $119.32. 44,794 shares of the stock traded hands, compared to its average volume of 1,394,139. The business has a 50-day moving average of $110.17 and a two-hundred day moving average of $99.49. The stock has a market capitalization of $14.65 billion, a PE ratio of -38.04 and a beta of 1.48. Natera has a 12-month low of $36.90 and a 12-month high of $124.83. The company has a debt-to-equity ratio of 0.36, a quick ratio of 3.98 and a current ratio of 4.12.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.39. The firm had revenue of $413.35 million for the quarter, compared to analyst estimates of $343.00 million. Natera had a negative net margin of 30.24% and a negative return on equity of 49.72%. The business’s quarterly revenue was up 58.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.97) earnings per share. On average, equities analysts forecast that Natera will post -2.43 earnings per share for the current fiscal year.

Insider Transactions at Natera

In other news, CEO Steven Leonard Chapman sold 5,583 shares of the stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $118.91, for a total value of $663,874.53. Following the completion of the transaction, the chief executive officer now owns 200,710 shares in the company, valued at approximately $23,866,426.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Natera news, CEO Steven Leonard Chapman sold 5,583 shares of the firm’s stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $118.91, for a total transaction of $663,874.53. Following the completion of the transaction, the chief executive officer now directly owns 200,710 shares in the company, valued at approximately $23,866,426.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gail Boxer Marcus sold 2,000 shares of the firm’s stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $110.17, for a total transaction of $220,340.00. Following the transaction, the director now owns 18,634 shares of the company’s stock, valued at $2,052,907.78. The disclosure for this sale can be found here. In the last quarter, insiders sold 94,388 shares of company stock worth $10,425,404. Company insiders own 7.60% of the company’s stock.

Institutional Investors Weigh In On Natera

Hedge funds and other institutional investors have recently modified their holdings of the company. SG Americas Securities LLC grew its holdings in shares of Natera by 1,073.1% during the second quarter. SG Americas Securities LLC now owns 65,730 shares of the medical research company’s stock worth $7,118,000 after buying an additional 60,127 shares in the last quarter. Thematics Asset Management grew its holdings in shares of Natera by 3.1% during the fourth quarter. Thematics Asset Management now owns 90,232 shares of the medical research company’s stock worth $5,652,000 after buying an additional 2,738 shares in the last quarter. Crestline Management LP grew its holdings in shares of Natera by 16.0% during the fourth quarter. Crestline Management LP now owns 65,070 shares of the medical research company’s stock worth $4,076,000 after buying an additional 8,997 shares in the last quarter. Hamilton Lane Advisors LLC purchased a new stake in shares of Natera during the fourth quarter worth about $616,000. Finally, Russell Investments Group Ltd. grew its holdings in shares of Natera by 15.1% during the first quarter. Russell Investments Group Ltd. now owns 74,460 shares of the medical research company’s stock worth $6,810,000 after buying an additional 9,781 shares in the last quarter. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.